Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico), 1986, Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction, Lancet, i, 397

ISAM (Intravenous Streptokinase in Acute Myocardial Infarction) Study Group, 1986, A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days, N Engl J Med, 314, 1465, 10.1056/NEJM198606053142301

AIMS (APSAC Intervention Mortality Study) Trial Study Group, 1988, Effects of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial, Lancet, i, 545

1988, Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2, Lancet, ii, 349

Wilcox, 1988, Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (ASSET), Lancet, ii, 525, 10.1016/S0140-6736(88)92656-6

1991, Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction, Am J Cardiol, 68, 585, 10.1016/0002-9149(91)90348-O

1992, ISIS-3: a randomised trial of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction, Lancet, 339, 753, 10.1016/0140-6736(92)91893-D

1993, Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction, Lancet, 342, 767, 10.1016/0140-6736(93)91539-X

LATE Study Group, 1993, Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction, Lancet, 342, 759, 10.1016/0140-6736(93)91538-W

Collins, 1991, British Heart Foundation Surveys (1987 & 1989) of United Kingdom policies for acute myocardial infarction, Br Heart J, 66, 250, 10.1136/hrt.66.3.250

Hlatky, 1988, Adoption of thrombolytic therapy in the management of acute myocardial infarction, Am J Cardiol, 61, 510, 10.1016/0002-9149(88)90755-2

Pfeffer, 1991, Selection bias in the use of thrombolytic therapy in acute myocardial infarction, JAMA, 266, 528, 10.1001/jama.1991.03470040092028

Gray, 1993, Impact of hospital thrombolysis policy on out-of-hospital response to suspected myocardial infarction, Lancet, 341, 654, 10.1016/0140-6736(93)90420-L

Ketley, 1993, Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction, Lancet, 342, 891, 10.1016/0140-6736(93)91945-I

Bates, 1988, Reperfusion therapy in inferior myocardial infarction, J Am Coll Cardiol, 12, 44A, 10.1016/0735-1097(88)92640-X

Bates, 1989, Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality, J Am Coll Cardiol, 13, 12, 10.1016/0735-1097(89)90542-1

Midgette, 1990, Effect of intravenous streptokinase on early mortality in patients with suspected acute myocardial infarction, Ann Intern Med, 113, 961, 10.7326/0003-4819-113-12-961

1989, Lancet, ii, 899

Califf, 1989, Myocardial reperfusion: is it ever too late?, J Am Coll Cardiol, 13, 1130, 10.1016/0735-1097(89)90274-X

White, 1992, Thrombolytic therapy for patients with myocardial infarction presenting after six hours, Lancet, 340, 221, 10.1016/0140-6736(92)90478-L

Gurwitz, 1991, Coronary thrombolysis for the elderly?, JAMA, 265, 1720, 10.1001/jama.1991.03460130112032

Topol, 1992, Thrombolytic therapy for elderly patients, N Engl J Med, 327, 45, 10.1056/NEJM199207023270109

Lew, 1987, Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase, Am J Cardiol, 59, 1, 10.1016/S0002-9149(87)80059-0

Weaver, 1991, Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction, J Am Coll Cardiol, 18, 657, 10.1016/0735-1097(91)90784-7

Bates, 1991, Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock, J Am Coll Cardiol, 18, 1077, 10.1016/0735-1097(91)90770-A

Muller, 1990, Selection of patients with acute myocardial infarction for thrombolytic therapy, Ann Intern Med, 113, 949, 10.7326/0003-4819-113-12-949

Gore, 1991, Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction study, Circulation, 83, 448, 10.1161/01.CIR.83.2.448

Sloan, 1992, Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: a risk-benefit analysis, Am J Cardiol, 69, 21A, 10.1016/0002-9149(92)91169-5

De Jaegere, 1992, Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors, J Am Coll Cardiol, 19, 289, 10.1016/0735-1097(92)90480-B

Chapman, 1993, Minimizing the risk of inappropriately administering thombolytic therapy (Thrombolysis and Angioplasty in Myocardial Infarction [TAMI] Study Group), Am J Cardiol, 71, 783, 10.1016/0002-9149(93)90824-V

Peto, 1987, Why do we need some systematic overviews of randomized trials?, Stat Med, 6, 233, 10.1002/sim.4780060306

Collins, 1987, Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews, Stat Med, 6, 245, 10.1002/sim.4780060308

Braunwald, 1990, Optimizing thrombolytic therapy of acute myocardial infarction, Circulation, 82, 1510, 10.1161/01.CIR.82.4.1510

Grines, 1990, Optimal utilization of thrombolytic therapy for acute myocardial infarction: concepts and controversies, J Am Coll Cardiol, 16, 223, 10.1016/0735-1097(90)90482-5

Wasserman, 1989, Patient selection for thrombolytic therapy, Am J Cardiol, 64, 17B, 10.1016/S0002-9149(89)80004-9

Cragg, 1991, Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy, Ann Intern Med, 115, 173, 10.7326/0003-4819-115-3-173

Collins, 1991, Optimizing thrombolytic therapy of acute myocardial infarction: age is not a contraindication, Circulation, 84, II

1990

1994, Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarctions and stroke by prolonged antiplatelet therapy in various categories of patients, BMJ, 308, 81, 10.1136/bmj.308.6921.81

Efron, 1977, Stein's paradox in statistics, Sci Am, 236, 119, 10.1038/scientificamerican0577-119

Yusuf, 1985, Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials, Eur Heart J, 6, 556, 10.1093/oxfordjournals.eurheartj.a061905

Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico (GISSI), 1987, Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study, Lancet, ii, 872

AIMS Trial Study Group, 1990, Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study, Lancet, 335, 427, 10.1016/0140-6736(90)90663-P

Wilcox, 1990, Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study, Lancet, 335, 1175

1993, ISIS-2: 4-year mortality follow-up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction, Circulation, 86 (suppl I), I

MacMahon, 1990, Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias, Lancet, 335, 765, 10.1016/0140-6736(90)90878-9

Braunwald, 1989, Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival, Circulation, 79, 441, 10.1161/01.CIR.79.2.441

Schroder, 1989, Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (results from the ISAM study), Am J Cardiol, 64, 878, 10.1016/0002-9149(89)90835-7

Maggioni, 1992, The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment, N Engl J Med, 327, 1, 10.1056/NEJM199207023270101

The GUSTO Investigators, 1993, An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction, N Engl J Med, 329, 673, 10.1056/NEJM199309023291001

Hutter, 1989, Coronary angioplasty in acute myocardial infarction: should it be done? To whom? When?, J Am Coll Cardiol, 13, 1127, 10.1016/0735-1097(89)90273-8

Lange, 1993, Immediate angioplasty for acute myocardial infarction, N Engl J Med, 328, 726, 10.1056/NEJM199303113281010

Mauri, 1987, GISSI: analisi delle cause di morte intraospedaliera, G Ital Cardiol, 17, 37

Braunwald, 1985, Myocardial reperfusion: a double-edged sword?, J Clin Invest, 76, 1713, 10.1172/JCI112160

1989, Lancet, ii, 655

Honan, 1990, Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis, J Am Coll Cardiol, 16, 359, 10.1016/0735-1097(90)90586-E

Loukinen, 1989, Myocardial rupture complicating tissue plasminogen activator therapy of acute myocardial infarction, J Am Coll Cardiol, 13, 94A

Massel, 1993, How sound is the evidence that thrombolysis increases the risk of cardiac rupture?, Br Heart J, 69, 284, 10.1136/hrt.69.4.284